Prevalence of autoantibodies against 3-DG-glycated H2A protein in type 2 diabetes


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Advanced glycation end-products (AGEs) have been found to be critically involved in initiation or progression of diabetes secondary complications (nephropathy, retinopathy, neuropathy, and angiopathy). Various hyper-glycating carbonyl compounds such as 3-deoxyglucosone (3-DG) are produced in pathophysiological conditions that form AGEs in high quantity both in vivo and in vitro. In the first stage of this study, we glycated histone H2A protein by 3-DG, and the results showed the formation of various intermediates and AGEs as well as structural changes in the protein. In the second stage, we studied the immunogenicity of native and 3-DG-glycated H2A protein in female rabbits. The modified H2A was highly immunogenic, eliciting high titer immunogen-specific antibodies, while the unmodified form was almost nonimmunogenic. Antibodies against standard carboxymethyllysine (CML) and pentosidine were detected in the immunized female rabbits, which demonstrates the immunogenic nature of AGEs (CML and pentosidine) as well. The results show both structural perturbation and AGEs have the capacity of triggering the immune system due to the generation of neoepitopes that render the molecule immunogenic. This study shows the presence of autoantibodies against 3-DG-modified H2A, CML, and pentosidine in the sera of type 2 diabetes patients having secondary complications. Autoantibodies against damaged H2A and AGEs may be significant in the assessment of initiation/progression of secondary complications in type 2 diabetes mellitus patients or may be used as a marker for early detection of secondary complications in diabetes.

Об авторах

J. Ashraf

Faculty of Applied Medical Sciences

Автор, ответственный за переписку.
Email: jmashraf@gmail.com
Саудовская Аравия, Jazan

S. Abdullah

Faculty of Applied Medical Sciences

Email: jmashraf@gmail.com
Саудовская Аравия, Jazan

S. Ahmad

Department of Biotechnology

Email: jmashraf@gmail.com
Индия, Lucknow

S. Fatma

Faculty of Science

Email: jmashraf@gmail.com
Индия, Varanasi

M. Baig

Department of Medical Biotechnology

Email: jmashraf@gmail.com
Республика Корея, Gyeongsan

J. Iqbal

Faculty of Medicine

Email: jmashraf@gmail.com
Саудовская Аравия, Jazan

A. Madkhali

Faculty of Applied Medical Sciences

Email: jmashraf@gmail.com
Саудовская Аравия, Jazan

A. Jerah

Faculty of Applied Medical Sciences

Email: jmashraf@gmail.com
Саудовская Аравия, Jazan


© Pleiades Publishing, Ltd., 2017

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах